About
Medable is a comprehensive clinical trial platform purpose-built for modern drug development. It brings together agentic AI, eCOA (electronic Clinical Outcome Assessment), eConsent, remote site monitoring, and decentralized clinical trial (DCT) infrastructure into a single, unified solution. Sponsors can build studies up to 35x faster using Medable Studio's AI-assisted authoring environment, while a suite of specialized AI agents—including the TMF Agent, Site Monitoring Agent, and PI Summary & Review Agent—automate repetitive manual processes and eliminate clinical trial 'white space.' The platform supports real-time patient-reported data collection, participant reminders, study notifications, and data visualization in one place. It is offered in over 60 countries and 120 languages and runs on a cloud-agnostic, single-API architecture that integrates with leading clinical systems. Medable serves 14 of the top 20 global pharma companies and is rated the #1 DCT platform, delivering a reported 13x ROI for Phase III trials. Its extensive partner network spans retail pharmacies, site networks, real-world evidence (RWE) providers, and home health services, making it ideal for mid-to-large pharma, emerging biopharma, and CROs seeking to modernize and accelerate clinical development.
Key Features
- Agentic AI for Trial Automation: Purpose-built AI agents—including the TMF Agent, Site Monitoring Agent, and PI Summary & Review Agent—automate time-consuming manual tasks, reduce site burden, and maximize investigator capacity.
- Best-in-Class eCOA: Electronic Clinical Outcome Assessment tools enable accurate, real-time patient-reported data collection, simplifying workflows and reducing data entry errors across trial sites.
- Medable Study Studio: An AI-assisted study authoring environment that allows sponsors to build and configure clinical studies up to 35x faster than traditional methods, with full control and transparency.
- Decentralized Clinical Trial (DCT) Platform: Supports remote data collection, eConsent, participant reminders, and real-time reporting—enabling fully or hybrid decentralized trials across 60+ countries and 120+ languages.
- Extensive Integration & Partner Network: A cloud-agnostic, single-API platform with a library of system integrations and a broad partner network spanning retail pharmacy, site networks, RWE/LTFU data providers, and home health services.
Use Cases
- Running decentralized or hybrid clinical trials with remote patient data collection, eConsent, and home health integration.
- Automating Trial Master File (TMF) management using the Medable TMF Agent to reduce site administrative burden.
- Accelerating study build and configuration for Phase II and Phase III pharmaceutical trials using Medable Studio and AI.
- Streamlining investigator site workflows and maximizing PI capacity with the PI Summary & Review Agent.
- Collecting real-time electronic patient-reported outcomes (ePRO) across multinational studies in multiple languages.
Pros
- Proven ROI and Industry Recognition: Delivers a reported 13x ROI for Phase III trials and is rated the #1 DCT platform, trusted by 14 of the top 20 global pharmaceutical companies.
- Global Scale and Flexibility: Available in 60+ countries and 120+ languages on a cloud-agnostic, API-first architecture, making it suitable for multinational studies of any size.
- End-to-End Trial Coverage: Unifies eCOA, eConsent, site monitoring, AI agents, and participant engagement in a single platform, eliminating the need for multiple disconnected tools.
- AI-Driven Speed: Study Studio and AI agents dramatically cut study build times and automate repetitive processes, reducing white space and accelerating time to patient.
Cons
- Non-Transparent Enterprise Pricing: Pricing is not publicly listed and requires a demo request, making it difficult for smaller organizations to quickly assess cost-fit.
- Primarily Suited for Large Organizations: The platform's depth and enterprise focus may represent more complexity and cost than early-stage startups or academic researchers need.
- Implementation Complexity: As a comprehensive enterprise platform with multiple integrated modules, onboarding and configuration may require significant time and technical resources.
Frequently Asked Questions
What is Medable?
Medable is an enterprise clinical trial platform that combines agentic AI, eCOA, eConsent, remote site monitoring, and decentralized clinical trial (DCT) capabilities into a single unified solution for pharma, biotech, and CRO organizations.
What is eCOA and how does Medable use it?
eCOA (electronic Clinical Outcome Assessment) is a method for collecting patient-reported, clinician-reported, and observer-reported outcomes electronically. Medable's eCOA solutions enable real-time, accurate data collection from patients and sites, reducing errors and streamlining trial workflows.
How do Medable's AI agents work?
Medable's AI agents—such as the TMF Agent, Site Monitoring Agent, and PI Summary & Review Agent—are purpose-built autonomous tools that perform series of tasks automatically. They reduce manual burden at research sites, automate Trial Master File processes, and help investigators manage their workloads more efficiently.
Who is Medable designed for?
Medable serves mid-to-large pharmaceutical companies, emerging biopharma, and CROs. It is particularly well-suited for organizations running complex, multi-country, or decentralized clinical trials at scale.
In how many countries and languages is Medable available?
Medable is available in over 60 countries and supports more than 120 languages, making it a strong choice for global clinical development programs.
